Sie suchten nach: interrupting (Englisch - Maltesisch)

atripla can be reinitiated in patients interrupting therapy because of rash.
atripla jista’ jerġa’ jinbeda f’pazjenti li jkunu interrompew it-terapija minħabba raxx.

some side effects can be managed by interrupting treatment or reducing the dose.
xi effetti sekondarji jistgħu jiġu ġestiti bit- twaqqif tat- trattament jew bit- tnaqqis tad- doża.

efavirenz can be re-initiated in patients interrupting therapy because of rash.
efavirenz jista’ jinbeda mill-ġdid f’pazjenti li jwaqqfu t-terapija minħabba r-raxx.

interrupting or stopping the treatment with xolair may cause your asthma symptoms to come back.
jekk twaqqaf il-kura bi xolair għal xi żmien jew għall-kollox, jistgħu jerġgħu joħorġu s-sintomi ta’ l-ażma.

colestyramine can increase the non-renal elimination of methotrexate by interrupting the enterohepatic circulation.
colestyramine jista’ jżid l-eliminazzjoni mhux mill-kliewi ta’ methotrexate billi jxekkel iċ- ċirkolazzjoni enteroepatika.

this is thought to be achieved by a gastrointestinal dialysis mechanism and/or by interrupting enterohepatic recycling.
huwa maħsub li dan jintlaħaq permezz ta’ mekkaniżmu ta’ dijaliżi gastro-intestinali u/jew billi jkun interrott ir-reċiklaġġ enteroepatiku.

the date for calculating the limitation period and the conditions for interrupting this period shall be laid down in the implementing rules.
id-data biex jiġi kkalkulat il-perijodu ta’ limitazzjoni u l-kondizzjonijiet għall-interruzzjoni tal-perijodu għandhom jitniżżlu fir-regoli implimentattivi.

figure 3.4 room acoustic influences may be assessed by interrupting a sound and measuring its decay due to surface reflections.
figura 3.4 l-influwenzi akustiċi ta' kamra jistgħu jiġu evalwati bl-interruzzjoni ta' ħoss u l-kejl tattnaqqis tiegħu b'riżultat tar-riflessjonijiet ma' l-uċuħ.

interrupting this positive trend, however, the economic crisis has had serious repercussions on the labour market and unemployment figures.
minkejja dan, il-kriżi eknomika interrompiet din ix-xejra pożittiva, u kellha riperkussjonijiet serji fuq is-suq tax-xogħol u ċ-ċifri tal-qgħad.

76 interrupting therapy with other antiretroviral agents to avoid development of resistant virus (see section 4.8).
jekk titwaqqaf it- terapija b’ efavirenz, għandha titqies il- possibilita` li tiġi interrotta t- terapija b’ aġenti antiretrovirali oħra biex ma jiżviluppax virus reżistenti (ara sezzjoni 4. 8).

patients who develop an infection while undergoing treatment with benlysta should be monitored closely and careful consideration given to interrupting immunosuppressant therapy including belimumab until the infection is resolved.
pazjenti li jiżviluppaw infezzjoni waqt li jkunu qed jieħdu kura b’benlysta għandhom jiġu mmonitorjati mill-qrib u għandha tingħata konsiderazzjoni b’reqqa għall-interruzzjoni ta’ terapija immunosoppressanti inkluż belimumab sakemm l-infezzjoni tiġi riżolta.

an automatic weighing instrument that continuously determines the mass of a bulk product on a conveyor belt, without systematic subdivision of the product and without interrupting the movement of the conveyor belt.
strument awtomatiku tal-kejl li jistabbilixxi b'mod kontinwu l-massa ta' prodott bil-massa fuq ċinga trasportatur, mingħajr is-suddiviżjoni sistematika tal-prodott u mingħajr ma jinterrompi l-moviment taċ-ċinga trasportatur.

whereas such provisions should specify the length of limitation periods, the date on which time starts to run and the events which have the effect of interrupting or suspending the limitation period;
billi disposizzjonijiet bħal dawn għandhom jispeċifikaw it-tul tal-perjodi ta' limitazzjoni, id-data meta ż-żmien jibda jiddekorri u l-ġrajjiet li għandhom l-effett li jinterrompu jew jissospendu l-perjodu ta' limitazzjoni;

for strong cyp3a inhibitors used short-term (7 days or less), consider interrupting cobimetinib therapy during the duration of inhibitor use.
għal inibituri qawwija ta’ cyp3a użati għal żmien qasir (7 ijiem jew inqas), ikkunsidra interruzzjoni tat-terapija ta’ cobimetinib matul il-perjodu ta’ użu tal-inibitur.

interrupting or suspending all or part of payments in accordance with articles 41 and 42 if the national management and control systems fail, and by applying any other financial correction required, in accordance with the procedures described in articles 45 and 46.
jinterrompu jew iwaqqfu l-pagamenti kollha jew partijiet minnhom skond l-artikoli 41 u 42, jekk is-sistemi nazzjonali ta’ tmexxija u kontroll jkunu naqsu b’xi mod, u billi japplikaw kwalunkwe korrezzjoni finanzjarja oħra, skond il-proċeduri deskritti fl-artikoli 45 u 46.

if therapy with efavirenz is discontinued, consideration should also be given to interrupting therapy with other antiretroviral agents to avoid development of resistant virus (see section 4.8).
jekk titwaqqaf it-terapija b’efavirenz, għandha titqies il-possibilita` li tiġi interrotta t-terapija b’aġenti antiretrovirali oħra biex ma jiżviluppax virus reżistenti (ara sezzjoni 4.8).

should a significant increase occur, reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly (see sections 4.4 and 4.8).
jekk isseħħ żieda sinifikanti, it-tnaqqis tar-rata tal-amministrazzjoni jew l-interruzzjoni temporanja tal-injezzjoni normalment jippermettu li s-sintomi jisparixxu minnufih (ara sezzjonijiet 4.4 u 4.8).

in the naglazyme clinical trials, iars were usually manageable by interrupting or slowing the rate of infusion and by (pre-) treating the patient with antihistamines and/or antipyretics (paracetamol), thus enabling the patient to continue treatment.
fil-provi kliniċi b’naglazyme, iars ġeneralment kienu maniġġabbli bl-interruzzjoni jew tnaqqis fir-rata ta’ l-infużjoni u b’kura minn qabel tal-pazjent b’antistamini u/jew sustanzi kontra d-deni (paracetamol), u b’hekk ikun possibbli għall-pazjent li jkompli l-kura.